Retatrutide sleep apnea trials found fewer breathing interruptions than placebo, a treatment without the active drug. The difference was substantial after 80 weeks. But the studies didn't compare retatrutide with tirzepatide, and they don't establish when someone can stop using a breathing machine.
The news concerns obstructive sleep apnea, or OSA: repeated narrowing or closing of the airway during sleep. Retatrutide remains an experimental medicine. A positive trial result and a treatment someone can discuss for use today are different stages of the story.
Retatrutide sleep apnea results: what happened
As of October 29, 2026, the day this article was written, results published October 21 in the New England Journal of Medicine describe two late-stage trials. Both tested retatrutide against placebo, with treatment assigned by chance and hidden from participants and investigators.
TRIUMPH-1-OSA included 243 adults without type 2 diabetes. TRIUMPH-2-OSA included 448 adults with it. Everyone had moderate-to-severe OSA and a body-mass index, a measure of weight relative to height, of at least 27.
The main measurement was the apnea–hypopnea index, or AHI: breathing pauses or shallow breaths per hour of sleep. Here are the 9 mg and 12 mg results at 80 weeks. These were study doses, not a prescribing schedule.
| Trial and study dose | AHI decrease with retatrutide | AHI decrease with placebo | Additional decrease versus placebo |
|---|---|---|---|
| TRIUMPH-1-OSA, 9 mg | 34.3 events/hour | 9.9 | 24.4 |
| TRIUMPH-1-OSA, 12 mg | 31.7 events/hour | 9.9 | 21.9 |
| TRIUMPH-2-OSA, 9 mg | 24.7 events/hour | 10.3 | 14.4 |
| TRIUMPH-2-OSA, 12 mg | 25.4 events/hour | 10.3 | 15.1 |
These are estimates from the paper's main analysis, a “hybrid-treatment estimand”: for participants with events suggesting treatment failure, it estimated what would have happened without those events, and for everyone else it counted results as they occurred. An analysis keeping people in their assigned groups gave similar results. Lilly funded the trials.
What that breathing change means
The participants started with averages of roughly 56 to 59 breathing events an hour. That is well into the severe range. The American Academy of Sleep Medicine's 2009 clinical guideline places more than 30 events an hour in that range.
A drop of 15 or 24 events an hour can therefore represent a substantial change while leaving breathing problems behind. The average improvement doesn't tell us that everyone reached the same severity category. A follow-up sleep study measures what remains for an individual.
What it means alongside Zepbound
Zepbound, the branded tirzepatide product, already has a sleep-apnea indication, meaning a use listed in its prescribing label. Its current prescribing information, marked “Revised: 8/2026,” includes “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.” The label pairs treatment with a reduced-calorie diet and increased physical activity.
That indication belongs to Zepbound. Compounded means a licensed pharmacy prepares a medication for an individual prescription. Compounded tirzepatide is different from an FDA-approved product: the formulation offered here is not FDA-approved. Our guide to tirzepatide for sleep apnea explains the distinction.
What it means for a compounded tirzepatide prescription
Through Promise, tirzepatide is dispensed as a compounded medication by a licensed U.S. compounding pharmacy. It is a separate preparation from Zepbound.
Neither the retatrutide trials nor Zepbound's indication establishes equivalent effects for a compounded preparation. The 2024 SURMOUNT-OSA paper in the New England Journal of Medicine tested tirzepatide against placebo. The separate SURMOUNT-OSA results guide covers those findings.
A licensed provider may still prescribe — that decision is between you and your doctor. A new retatrutide paper doesn't determine whether an existing tirzepatide prescription fits someone's history or goals.
What the trials don't establish
They don't show that retatrutide works better than tirzepatide. Comparing numbers from separate studies mixes different participants, study lengths and analysis methods. A trial assigning people directly to the two medicines would answer a different question.
They also don't establish a reason to stop prescribed airway treatment. AASM describes CPAP, a machine that holds the airway open with steady air pressure, alongside options including fitted mouthpieces and surgery. Its guideline calls for reassessment after substantial weight loss before deciding whether airway pressure treatment is still needed.
Side effects belong in the picture too. The retatrutide abstract identifies stomach and bowel problems as the most common side effects. It gives no individual symptom rates. That summary cannot establish which medicine would be easier for a particular person to tolerate.
Retatrutide remains investigational
Lilly states that no regulator anywhere has approved retatrutide. The FDA's GLP-1 page, marked “Content current as of: 10/01/2026,” states: “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.”
That is the agency's stated position, separate from the question these trials asked about breathing. A publication doesn't establish the contents or quality of something sold online under the same name. Our report on counterfeit retatrutide explains that problem.
Where semaglutide fits
Semaglutide is another medicine considered for weight management. But neither the Wegovy label, revised 6/2026, nor the Ozempic label, revised 5/2026, lists OSA as an indication. Retatrutide's results don't add one.
The guide to semaglutide for sleep apnea separates weight-management evidence from measured breathing outcomes. Our retatrutide versus Ozempic report addresses the separate diabetes comparison.
Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The retatrutide study supplies no breathing-benefit estimate for it.
What to watch next
The useful next developments are an application for regulatory review, a decision, and any eventual prescribing label. Those would clarify which patients and uses a finished product covers. Publication alone doesn't settle them.
For sleep care, the questions remain concrete: how many breathing events remain, how symptoms change, and how medication fits with existing airway treatment. A sleep clinician interprets those together. The prescriber sets any medication dose and follow-up plan.
At Promise, a licensed U.S. provider reviews every request and prescribes only when medically appropriate. Not everyone qualifies.
The new trials add evidence that retatrutide can change measured breathing in the groups studied. They leave treatment choices with the clinicians and patients who have to weigh the whole picture.
